Rituximab in the Treatment of Thyroid Eye Disease: A Review

REFERENCES

• Bahn RS. Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev Clin Pharmacol 2012;5:605–607
   Web of Science ®Google Scholar
• Salvi M, Vanucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves' orbitopathy. J Clin Endocrinol Metab 2013;98:4291–4299
   PubMed Web of Science ®Google Scholar
• Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G; European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J Clin Endocrinol Metab 2012;97:4454–4463
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284–290
   PubMed Web of Science ®Google Scholar
• Velasco e Cruz AA, Vagner de Oliveira M. The effect of Mullerectomy on Kocher sign. Ophthal Plast Reconstr Surg 2001;17:309–315; discussion 15–16
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726–738
   PubMed Web of Science ®Google Scholar
• Michalek K, Morshed SA, Latif R, Davies RF. TSH receptor autoantibodies. Autoimmunity Rev 2009;9:113–116
   PubMed Web of Science ®Google Scholar
• Bahn RS. Autoimmunity and Graves' disease. Clin Pharmacol Ther 2012;91:577–579
   PubMed Web of Science ®Google Scholar
• Li H, Wang T. The autoimmunity in Graves's disease. Front Biosci 2013;18:782–787
   PubMed Web of Science ®Google Scholar
• Zheng L, Ye P, Liu C. The role of the IL-23/IL-17 axis in the pathogenesis of Graves' disease. Endocr J 2013;60:591–597
   PubMed Web of Science ®Google Scholar
• Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B. Why is the thyroid so prone to autoimmune disease? Hormone Res Paediatr 2011;75:157–165
   PubMed Web of Science ®Google Scholar
• Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol 2013;9:277–287
   PubMed Web of Science ®Google Scholar
• Eschler DC, Hasham A, Tomer Y. Cutting edge: the etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol 2011;41:190–197
   PubMed Web of Science ®Google Scholar
• Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006;142:147–153
   PubMed Web of Science ®Google Scholar
• Dickinson AJ. Clinical Manifestations. In: Wiersinga WM, Kahaly GJ, editors. Graves' orbitopathy: a multidisciplinary approach: Questions and Answers. 2nd ed. Basel: S Karger; 2010;1–25
   Google Scholar
• Lehmann GM, Garcia-Bates TM, Smith TJ, Feldon SE, Phipps RP. Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation. PPAR Res 2008;2008:895–901
   Google Scholar
• Fruch BR, Musch DC, Garber FW. Lid retraction and levator aponeurosis defects in Graves' eye disease. Ophthalmic Surg 1986;17:216–220
   Google Scholar
• Shen S, Chan A, Sfikakis PP, et al. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol 2013;58:252–265
   Google Scholar
• El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L. The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006;154:623–632
   PubMed Web of Science ®Google Scholar
• Mitchell AL, Gan EH, Morris M, Johnson K, Neoh C, Dickenson AJ, Perros P, Pearce SH. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy. Clin Endocrinol 2013;79:437–442
   PubMed Web of Science ®Google Scholar
• El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L. Evidence of Intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab 2007;92:3762–3763
   PubMed Web of Science ®Google Scholar
• El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009;130:252–258
   PubMed Web of Science ®Google Scholar
• Vanucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Currò N, Simonetta S, Bonara P, Persani L, Guastella C, Wall J, Beck-Peccoz P, Salvi M. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 2010;161:436–443
   Google Scholar
• El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16:709–710
   PubMed Web of Science ®Google Scholar
• Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, Goldberg RA, Darwin CH, Smith TJ, Douglas RS. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010;117:133–139
   PubMed Web of Science ®Google Scholar
• Krassas GE, Stafilidou A, Boboridis KG. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol (Oxf) 2010;72:853–855
   PubMed Web of Science ®Google Scholar
• Madaschi S, Rossini A, Formenti I, Lampasona V, Marzoli SB, Cammarata G, Politi LS, Martinelli V, Bazzigaluppi E, Scavini M, Bosi E, Lanzi R. Treatment of thyroid-associated orbitopathy with rituximab—a novel therapy for an old disease: case report and literature review. Endocr Pract 2010;16:677–685
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: anopen study. Eur J Endocrinol 2007;156:33–40
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P. Small dose of rituximab for Graves' orbitopathy: new insights into the mechanism of action. Arch Ophthalmol 2012;130:122–124
   PubMedGoogle Scholar
• Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 2010;126:310–314
   Google Scholar
• Mourits M, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997;47:9–14
   PubMed Web of Science ®Google Scholar
• Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977;44:203–204
   PubMed Web of Science ®Google Scholar
• Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ 2004;329:385–390
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal anbitody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrin Metab 2007;92:1769–1772
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TWJ, Romijn JA, Smit JW. Rituximab in relapsing Graves' disease, a phase ii study. Eur J Endocrinol 2008;159:609–615
   PubMed Web of Science ®Google Scholar
• Bahn R, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR). Trial of Rituximab for Graves' Ophthalmopathy. ClinicalTrials.gov indentifier: NCT00595335. First received January 1, 2008. Last updated: June 6, 2014. Study completion date: March 2013. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00595335?term=rituximab+graves&rank=2. Accessed February 2, 2015
   Google Scholar
• Odense University Hospital. Rituximab in the Treatment of Graves' Disease. ClinicalTrials.gov identifier: NCT00150111. First received: September 6, 2005. Last updated: October 5, 2006. Available at: http://clinicaltrials.gov/ct2/show/study/NCT00150111?term=rituximab+graves&rank=3. Accessed February 2, 2015
   Google Scholar
• El Fassi D, Nielsen CH, Kieldsen J, Clemmensen O, Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008;57:714–715
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Junker P, Hasselbalch HC, Hegedüs L. Systemic adverse events following rituximab therapy in patients with Graves' disease. J Endocrinol Invest 2011;34:e163–e167
   PubMed Web of Science ®Google Scholar
• Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 2012;23(Suppl 10):x313–x319
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–3143
   PubMed Web of Science ®Google Scholar